Abiopharma

BICYCLE THERAPEUTICS PLC (BCYC) Announces Clinical Trial Update BICYCLE THERAPEUTICS PLC (BCYC) provided an update on its clinical development programs. Clinical Development Highlights:

• Drug Program: molecules, Association
• Diseases/Conditions: radiopharmaceutical use CAMBRIDGE
• Clinical Stage: Phase 2, Phase 1
• Collaboration: xenograft
  • targeting Nectin-4 and agonizing CD137; and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases in additional therapeutic areas. Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, Mass. For more information, visit bicycletherapeutics.com. Forward Looking Statements This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995
  • targeting EphA2, a historically undruggable target; a pipeline of other bicycle-based conjugate molecules, including Bicycle® Radioconjugates (BRC®) for radiopharmaceutical use; zelenectide pevedotin (formerly BT8009
  • targeting Bicycle® Drug Conjugate (BDC®), Phase 1/2 data in combination with nivolumab in metastatic urothelial cancer (mUC) patients. As of the February 9, 2026